Binds Drug, Hapten, Hapten-carrier Complex, Or Specifically-identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 530/389.8)
-
Publication number: 20120082667Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.Type: ApplicationFiled: April 16, 2010Publication date: April 5, 2012Applicant: IMMUNAS PHARMA, INC.Inventors: Tatsuki Yokoseki, Yasuhide Okamoto, Makoto Umeda, Toshiyuki Ito, Yukiho Imai, Shinobu Fujii, Naofumi Takamatsu
-
Publication number: 20120077964Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 27, 2011Publication date: March 29, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120076799Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: March 29, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120076796Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.Type: ApplicationFiled: December 10, 2009Publication date: March 29, 2012Applicant: Ablynx N.V.Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
-
Publication number: 20120071632Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.Type: ApplicationFiled: November 23, 2011Publication date: March 22, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20120071636Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.Type: ApplicationFiled: November 29, 2011Publication date: March 22, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20120070827Abstract: The present application relates to methods for identification of foetal cells and generation and isolation of binding members recognising foetal cells. Said methods may further be used for other purposes relating to characterisation of biological samples and biological antigens. The methods are characterised by the applicability in situations where the interesting objects are present in a limited amount, or where the interesting objects are intermixed with other material, thus the methods are suitable for use in situations where the ratio of the interesting material compared to other material is low. The application discloses methods for use of detecting foetal cells and method of generating/isolating binding members towards antigenic material of low abundancy.Type: ApplicationFiled: June 27, 2011Publication date: March 22, 2012Inventors: Steen Kølvraa, Britta Christensen, Palle Schelde, Morten Draeby Sorensen, Peter Kristensen
-
Publication number: 20120070443Abstract: Disclosed are compositions and methods related to inhibition of PDE1.Type: ApplicationFiled: December 2, 2009Publication date: March 22, 2012Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventor: Matthew Movsesian
-
Publication number: 20120065094Abstract: This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.Type: ApplicationFiled: September 14, 2011Publication date: March 15, 2012Applicant: NEW YORK UNIVERSITYInventors: Mukundan Attur, Steven B. Abramson
-
Publication number: 20120066777Abstract: Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.Type: ApplicationFiled: May 13, 2010Publication date: March 15, 2012Applicants: SHIONOGI & CO., LTD., RIKEN, SHIGA UNIVERSITY OF MEDICAL SCIENCEInventors: Yoshihiro Kawamura, Masatomo Rokushima, Minoru Suzuki, Tatsuya Takahashi, Minoru Ikeda, Atsunori Kashiwagi, Hiroshi Maegawa, Tohru Tani, Shiro Maeda
-
Patent number: 8133694Abstract: The preparation of vitamin D compounds of formula (I) with a label attached to a spacer group in the 3 position is disclosed. In the above formula (I), O represents the oxygen atom of an ether group; Y represents hydrogen or hydroxy; A represents a label such as biotin, digoxigenin, or another vitamin D group; R represents a substituted hydrocarbon side-group of vitamin D or a vitamin D metabolite. Also disclosed is a method of measuring 25-hydroxy vitamin D metabolite and a 1?,25-dihydroxy vitamin D metabolite in a sample.Type: GrantFiled: March 3, 2004Date of Patent: March 13, 2012Assignees: Immundiagnostik AG, Biomedica GmbHInventors: Franz Paul Armbruster, Wolfgang Voelter, Jens Tampe, Christian Birkmayer
-
Patent number: 8124743Abstract: The present invention discloses a method of purifying bivalent antibodies or antibody fragments that are active at both Fab sites from a source of antibodies or antibody fragments using a non-chromatographic method that includes inducing the formation of cyclic immunoglobulin aggregates by addition of multivalent hapten to a salt solution of soluble antibodies or antibody fragments, wherein the multivalent hapten possesses a linker between the two haptens effective to prevent the binding of both haptens of the ligand to the same antibody or antibody fragment.Type: GrantFiled: June 1, 2007Date of Patent: February 28, 2012Assignee: President and Fellows of Harvard CollegeInventors: Vijay M. Krishnamurthy, Lara A. Estroff, Vincent Semetey, Samuel W. Thomas, George K. Kaufman, Zihni Basar Bilgicer, George M. Whitesides
-
Publication number: 20120045443Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.Type: ApplicationFiled: August 5, 2011Publication date: February 23, 2012Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
-
Publication number: 20120045782Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.Type: ApplicationFiled: November 2, 2011Publication date: February 23, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov
-
Publication number: 20120045779Abstract: It is an object of the present invention to provide: a method for determining endometriosis, in which a blood sample from a subject can be used, and which is capable of determining endometriosis with higher sensitivity and higher precision than those of a conventional method using only a conventional endometriosis marker such as CA125; and a diagnostic kit for carrying out the method of the present invention. The method for determining endometriosis according to the present invention comprises: a step of analyzing an expression of at least one selected from among an anti-syntaxin autoantibody, an anti-PDIK1L autoantibody and an anti-enolase autoantibody; and a step of determining the presence or absence of the onset of endometriosis based on results of said expression analysis.Type: ApplicationFiled: February 23, 2010Publication date: February 23, 2012Inventors: Yasuhito Abe, Motowo Nabeta, Masaharu Ito
-
Publication number: 20120045465Abstract: The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.Type: ApplicationFiled: April 22, 2010Publication date: February 23, 2012Inventor: Haruo Sugiyama
-
Publication number: 20120039984Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: ApplicationFiled: July 2, 2009Publication date: February 16, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: Geert-Jan Boons, Therese Buskas, Alex J. Harvey, Sampat Ingale, Margaretha Wolfert, Robert Lance Wells
-
Publication number: 20120040378Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Publication number: 20120039912Abstract: The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption.Type: ApplicationFiled: April 13, 2010Publication date: February 16, 2012Applicants: GALAPAGOS SASU, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Georges Rawadi, Christof Niehrs
-
Publication number: 20120034631Abstract: The present invention provides crystalline forms of an anti-LPA antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided, as are methods of using structural information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Optimized variant anti-LPA antibodies are also provided.Type: ApplicationFiled: June 5, 2011Publication date: February 9, 2012Inventor: Jonathan Michael WOJCIAK
-
Publication number: 20120027780Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.Type: ApplicationFiled: January 20, 2011Publication date: February 2, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
-
Publication number: 20120027772Abstract: The present invention generally concerns formulations having a pH that inhibits aspartyl isomerization at an Asp-Asp motif in a therapeutic protein contained in such a formulation.Type: ApplicationFiled: November 19, 2009Publication date: February 2, 2012Inventors: Bruce Kabakoff, Daren Nelson, Jun Ouyang, Trevor Eli Swartz
-
Publication number: 20120027773Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.Type: ApplicationFiled: July 6, 2011Publication date: February 2, 2012Inventors: Kerry Whalen, Steve Botega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, JR., Jeno Gyuris
-
Publication number: 20120021437Abstract: Tetranor-PGDM/tetranor-PGJM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses in assay kits for detecting and quantifying tetranor-PGDM and tetranor-PGJM in biological fluids for determining biosynthesis of PGD2 in a subject or patient.Type: ApplicationFiled: June 14, 2011Publication date: January 26, 2012Applicant: Cayman Chemical Company, IncorporatedInventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov
-
Publication number: 20120021444Abstract: The present invention provides a method for diagnosis of cystic fibrosis, the method comprising: measuring an amount of KL-6 in a sample of body fluid from a subject, and determining, based on the amount of KL-6 measured, the degree of presence of cystic fibrosis in the subject.Type: ApplicationFiled: December 17, 2009Publication date: January 26, 2012Applicant: EIDIA Co., Ltd.Inventors: Shinichiro Ohshimo, Nobuoki Kohno, Ulrich Costabel
-
Publication number: 20120020958Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the corresponding mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof.Type: ApplicationFiled: December 30, 2008Publication date: January 26, 2012Applicant: Dansk UniversitetInventors: Uffe Holmskov, Anders Schlosser
-
Publication number: 20120016008Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26) and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: January 19, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010269Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human SMS3 (SMS3) and methods of use.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010270Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.Type: ApplicationFiled: September 24, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Publication number: 20120010557Abstract: The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and/or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.Type: ApplicationFiled: January 26, 2010Publication date: January 12, 2012Inventor: Michal Heger
-
Publication number: 20120009633Abstract: The invention provides nitrilases and methods for making and using them, and in one aspect, provides methods for producing enantiomerically pure ?-substituted carboxylic acids, such as, for example, ?-amino acids and ?-hydroxy acids. In one aspect, methods of the invention combine an aldehyde or ketone with a cyanide and ammonia or an ammonium salt or an amine, in the presence of a nitrilase or a polypeptide having nitrilase activity, to stereoselectively hydrolyze the amino nitrile or cyanohydrin intermediate under conditions sufficient to produce the carboxylic acid.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: Verenium CorporationInventors: Mark Madden, DARCY MADDEN, David Paul Weiner, Jennifer Ann Chaplin, Dan E. Robertson
-
Publication number: 20120010268Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 encoding HASH2 and methods of use.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: RYOGEN LLCInventor: James W. Ryan
-
Patent number: 8092794Abstract: The present invention relates to pharmaceutical compositions adapted for pharmaceutical administration comprising at least one superoxide dismutase and at least one prolamine based peptide fragment. The invention also relates to certain superoxide dismutases and prolamine based peptide fragments.Type: GrantFiled: March 15, 2006Date of Patent: January 10, 2012Assignee: Isocell Pharma S.A.Inventor: Alphonse Calenda
-
Publication number: 20120003245Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.Type: ApplicationFiled: December 4, 2009Publication date: January 5, 2012Inventors: J. Christopher Hall, Gabrielle Richard, Michael D. McLean
-
Publication number: 20120003236Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.Type: ApplicationFiled: July 5, 2011Publication date: January 5, 2012Applicant: Yeda Research And Development Co., Ltd.Inventors: Irit SAGI, Tamar Danon
-
Publication number: 20120004183Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.Type: ApplicationFiled: June 23, 2011Publication date: January 5, 2012Applicant: The Scripps Research InstituteInventors: Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
-
Publication number: 20120004117Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.Type: ApplicationFiled: December 25, 2009Publication date: January 5, 2012Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
-
Publication number: 20120003674Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.Type: ApplicationFiled: June 29, 2011Publication date: January 5, 2012Applicant: Randox Laboratories LimitedInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Patent number: 8088897Abstract: An isolated antibody produced against a donor product of an enzymatically catalyzed group transfer reaction is disclosed. In one aspect, the antibody has the ability to preferentially recognize the donor-product guanosine diphosphate (GDP), in the presence of the donor molecule guanosine triphosphate (GTP). Immunuoassays using compositions including such antibodies and kits for performing the immunoassays are also disclosed.Type: GrantFiled: April 25, 2008Date of Patent: January 3, 2012Assignee: BellBrook Labs, Inc.Inventors: Robert Lowery, Karen Kleman-Leyer, Matt Staeben, Thane Westermeyer
-
Publication number: 20110318339Abstract: Provided herein are anti-DLL4 antibodies and methods of using anti-DLL4 antibodies as therapeutic agents in diseases or disorders associated with DLL4.Type: ApplicationFiled: November 4, 2009Publication date: December 29, 2011Inventors: Vaughn Smider, Helen Hongyuan Mao, Cornelia Bentley, Tyson Chase
-
Publication number: 20110321197Abstract: A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities selected from the group consisting of 17.6 kDa class I heat shock protein, 26.Type: ApplicationFiled: October 2, 2009Publication date: December 29, 2011Applicant: BASF Plant Science GmbHInventors: Hardy Schön, Oliver Thimm, Gerhard Ritte, Oliver Bläsing, Koen Bruynseels, Yves Hatzfeld, Valerie Frankard, Ana Isabel Sanz Molinero, Christophe Reuzeau, Steven Vandenabeele
-
Publication number: 20110318368Abstract: The present invention relates to an anti-human ?9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ?9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ?9 integrin antibody; a diagnostic agent comprising the human ?9 integrin antibody; and a method for screening for a compound that inhibits the activity of human ?9 integrin.Type: ApplicationFiled: February 23, 2009Publication date: December 29, 2011Inventors: Shigeyuki Kon, Toshimitsu Uede
-
Publication number: 20110319592Abstract: The present invention relates to a novel process for the purification of antibodies, e.g. monoclonal antibodies. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of antibodies from even closely related proteins.Type: ApplicationFiled: November 13, 2009Publication date: December 29, 2011Applicant: Novo Nordisk A/SInventors: Phaedria Marie St. Hilaire, Anders Laerke Nielsen
-
Publication number: 20110318362Abstract: The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell.Type: ApplicationFiled: August 8, 2011Publication date: December 29, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventor: John C. Reed
-
Patent number: 8084586Abstract: Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.Type: GrantFiled: April 30, 2009Date of Patent: December 27, 2011Assignee: Saladax Biomedical, Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Publication number: 20110311449Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: February 10, 2011Publication date: December 22, 2011Applicant: AFFITECH RESEARCH ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Publication number: 20110305715Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use).Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Inventors: Lynn Y. Miao, Jennifer G. Johnson, Adriana Navarro, Paul Olivo, David Scholl
-
Publication number: 20110300160Abstract: Provided is a protein comprising an antibody binding site that binds to a sulfated epitope of a Wnt pathway protein that is not Wnt5A, Wnt11, or Wnt3a. Also provided is a composition comprising an isolated and purified Wnt pathway protein, where the protein is sulfated but not glycosylated. Additionally provided is a preparation of a Wnt pathway protein comprising at least one sulfation site and at least one glycosylation site, where all of the Wnt pathway protein in the preparation is glycosylated but not sulfated. Further provided is a composition comprising a peptide less than 75 amino acids or amino acid analogs, the peptide consisting of a fragment of a Wnt pathway protein, wherein the fragment is sulfated. A modified Wnt pathway protein comprising a sulfation site that is not present in the native Wnt pathway protein is also provided. Also provided is a method of detecting or quantifying a sulfated Wnt pathway protein in a preparation.Type: ApplicationFiled: April 15, 2011Publication date: December 8, 2011Inventors: Joshua Rabbani, James J. Donegan
-
Publication number: 20110300077Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 21, 2009Publication date: December 8, 2011Applicants: University of Zurich, Panima Pharmaceuticals AGInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20110296545Abstract: Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain ‘cleavage-inhibiting’ glutamine (Q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position ?5 relative to the cleavage site. Mutagenesis of Q at position ?5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(?5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods for treating conditions and/or diseases associated with M. haemolytica (e.g.Type: ApplicationFiled: February 2, 2010Publication date: December 1, 2011Applicant: Washington State UniversityInventors: Subramaniam Srikumaran, Sudarvili Shanthalingam